Sight Diagnostics, an Israeli medtech firm, has launched “OLO,” an AI-based blood diagnostics device which is said to offer lab-quality Complete Blood Count (CBC) tests from finger prick samples. Sight Diagnostics is an OurCrowd portfolio company.
AlmaLinks member Yossi Pollak, co-founder and CEO of Sight Diagnostics, says blood tests from only a finger prick are seen as the “holy grail” by many in the space.“It’s no secret that others have tried,” said Pollak, perhaps alluding to the Theranos debacle. “After implementing our malaria detection technology in India and several African countries and exceeding expectations in multiple clinical trials, we were encouraged to explore our technology’s ability to enter the $50 billion market of CBC testing. Now, we have clinically proven our lab-quality CBC analyzer, saving doctors and patients time, and helping improve outcomes for patients”.